A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
AN INTERVENTIONAL, PHASE 1b, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, MULTI-CENTER, DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SISUNATOVIR IN PEDIATRIC PARTICIPANTS UP TO AGE 60 MONTHS WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) LOWER RESPIRATORY TRACT INFECTION (LRTI)
Sponsor: Pfizer
Terminated
Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study
Other terminated trials from Pfizer
Other Respiratory Syncytial Virus Infections trials with similar outcome
This PHASE1 trial investigates Respiratory Syncytial Virus Infections and is currently terminated or withdrawn. Pfizer leads this study, which shows 13 recorded versions since 2024 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE1
-
Sep 2025 — Jan 2026 [monthly]
Terminated PHASE1
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE1
-
Nov 2024 — May 2025 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .